arrow
K

Kara N. Maxwell

University of Pennsylvania
H指数:36
被引数:6,143

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

21 A Phase II Study of Total Consolidative Metastasis-and-Primary Directed Therapy for Renal Cell Carcinoma (NCT06770855)

21 肾细胞癌完全巩固性转移灶及原发灶导向疗法的II期研究(NCT06770855)

2026-09-020
OAAI
Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans

克隆性造血对cfDNA液体活检检测的干扰及在美国退伍军人大型多样化队列中可操作变异的识别

2026-07-210
OAAI
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

生殖系TP53-driven乳腺癌中不同的基因组和免疫肿瘤进化

2026-05-210
OAAI
Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study

基因组风险模型在临床护理中实施精准前列腺癌筛查的进展研究

2026-01-260
PRE
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumors

生殖系致病变异影响儿童中枢神经系统肿瘤的体细胞改变和患者结局

2025-11-210
OAAI
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

一种基于贝叶斯定量分析的基因特异性变异分类方法:更新的专家小组建议改进了TP53生殖细胞变异在Li-Fraumeni综合征中的分类

2025-10-240
OAAI
Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men

HOXB13 G84E与592,158名男性中前列腺癌的关联

2025-10-010
PRE
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response

TP53突变型急性髓系白血病的化疗耐药性需要甲羟戊酸代谢产物法尼基焦磷酸,以诱导适应性应激反应。

Leukemia
IF13.4
2025-07-090
OAAI
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing

适应社会生态模型以解决黑人参与前列腺癌基因检测的差异

2024-09-180
OAAI
Risk of therapy-related subsequent cancers in individuals with germline TP53 variants
2024-09-050
PRE
INTEGRATED GERMLINE AND SOMATIC PROFILING OF PEDIATRIC BRAIN TUMORS REVEALS INCIDENTAL FINDINGS AND NOVEL TUMOR BIOLOGY
2024-06-180
OAAI
Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence
2024-05-032
PRE